NODAGA-NHS
NODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate 64Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [64Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1407166-70-4
- Formule: C19H28N4O10
- Masse moléculaire:472.45
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform EGFR
MoreVoir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
|
RDC Bifunctional Chelator |
HER2 |
[64Cu]NODAGA-trastuzumab (0.07-150 nM; 3 h) binds to HER2-positive SK-BR-3 breast adenocarcinoma cells with a Kd of 12.0 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1407166-70-4
-
Masse moléculaire 472.45
-
Formule C19H28N4O10
-
SMILES
OC(C(N(CCN1CC(O)=O)CCN(CC1)CC(O)=O)CCC(ON(C2=O)C(CC2)=O)=O)=O
-
Synonyms
NODA-GA-NHS ester
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Schjoeth-Eskesen C, et al. [(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice. J Labelled Comp Radiopharm. 2015;58(6):227-233. [Content Brief]
[2]. Gyuricza B, et al. Synthesis of Novel, Dual-Targeting 68Ga-NODAGA-LacN-E[c(RGDfK)]2 Glycopeptide as a PET Imaging Agent for Cancer Diagnosis. Pharmaceutics. 2021 May 26;13(6):796. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NODAGA-NHS Related Classifications
HY-156991 Related Classifications
Powered by Bioz